Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy

Trial Profile

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Azacitidine (Primary) ; CYAD 01 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms EPITHINK
  • Sponsors Celyad
  • Most Recent Events

    • 04 Dec 2018 Results of THINK, DEPLETHINK and EPITHINK trials assessing safety and clinical activity of multiple doses of Cyad-01, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
    • 30 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top